Stifel analyst Thomas Stephan raised the firm’s price target on RxSight to $68 from $64 and keeps a Buy rating on the shares, citing key takeaways from the company’s 2023 10-K and thoughts on consumer sentiment, valuation and IOL market statistics.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXST:
- Rxsight, Inc. (RXST) Q1 Earnings Cheat Sheet
- RxSight, Inc. to Report First Quarter Financial Results on May 6, 2024
- RxSight launches its newest light adjustable lens, the LAL+
- RxSight Announces Commercial Launch of its Newest Light Adjustable Lens™, the LAL+™, and Features Multiple Doctor Presentations at the Upcoming ASCRS Annual Meeting
- RxSight, Inc. to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Questions or Comments about the article? Write to editor@tipranks.com